Membrane transporters can have clinically relevant effects on the pharmacokinetics and pharmacodynamics of a drug in various organs and tissues by controlling its absorption, distribution and elimination. Together with metabolizing enzymes, they can drive a drug’s pharmacological action, as well as a drug can modulate transporter expression or activity, hence the importance of evaluating transporter-mediated drug-drug interactions recommended by the FDA guidelines. Genomembrane have developed transiently expressing ready-to-use cells to study FDA approved transporters (TransiPort). I had described this product range and their unique features in a previous post. I would like to introduce in this one 2 newly released cells overexpressing OATP1A2 and OATP2B1 transporters.
NADPH is a critical cofactor supporting numerous biochemical reactions. In ADME-Tox studies, NAD(P)H regeneration is strongly recommended when using drug metabolizing enzymes (ex. Cytochrome P450 (CYP), Flavin-containing MonoOxygenases (FMO)), Recombinant CYPs (incl. bactosomes) or cellular fractions (Microsomes, S9). Currently, the most simple and cost-effective way to regenerate the NAD(P)H in situ and enzymatically is to use the commercially-available RapidStart™ NADPH Regenerating System (Xenotech-Sekisui).
RapidStart uses an enzymatic reaction that changes NADP to NADPH, which is then oxidized by CYPs back to NADP, and the cycle continues…
Following the success of the previous EpiCypher meetings, we’re pleased to announce this year’s meeting by one of our partners EpiCypher.
EpiCypher2018: Biological and Clinical Frontiers in Epigenetics will feature keynote addresses by Dr. C. David Allis and Dr. Kristian Helin.
Dr. Allis is the Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University. Dr. Helin is a Professor at the University of Copenhagen and the director of the Danish National Research Foundation’s Centre for Epigenetics.
The plenary session talks will cover broad aspects of epigenetics and chromatin biology, ranging from basic molecular mechanisms to therapeutic efforts. There will be discussions around the elucidation of novel mechanisms, new tools, and other breaking topics in epigenetics and chromatin research.